Capital Raising & Corporate Finance
Israel’s Teva Bids $40 Billion For US Generic-Drug Rival
Capital Markets | M&A Pharmaceuticals
In what could become Israel’s biggest cross-border M&A deal ever, Teva Pharmaceutical Industries made an unsolicited $40 billion offer to acquire Mylan, a Pennsylvania-based drugmaker registered in the Netherlands with operational headquarters in the UK.